CTRI/2012/03/002470已完成3 期
Role of mifepristone (RU 486) in management of uterine leiomyoma
ICMR New Delhi0 个研究点目标入组 150 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Women having symptomatic leiomyoma uterus or leiomyoma of more than 5cm in size
排除标准
- •Uterine size more than 20 weeks , myoma size more than 15 cm on ultrasound, pregnancy, lactation, abnormal liver function, abnormal unexplained vaginal bleeding and use of steroid anticoagulant â?? HRT, GnRH within 3 months.
研究者
相似试验
已完成
不适用
Efficacy of mifepristone in the treatment of bipolar depressioBipolar DepressionMental and Behavioural DisordersBipolar depressionISRCTN27649427The Newcastle, North Tyneside And Northumberland Mental Health NHS Trust (UK)100
尚未招募
3 期
The role of Mifepristone in the treatment of uterine fibroids.CTRI/2024/01/061448Silchar Medical College and Hospital
已完成
2 期
Mifepristone (RU-486) in Androgen Independent Prostate CancerAdenocarcinoma of ProstateProstate CancerNCT00140478Dana-Farber Cancer Institute48
已完成
2 期
Mifepristone for Patients With Endometrial Cancer and LGESSEndometrial CancerNCT00505739M.D. Anderson Cancer Center13
终止
4 期
A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and EfficacyUterine FibroidNCT03210324China Resources Zizhu Pharmaceutical Co., Ltd.434